Literature DB >> 31506791

[Pathogenesis of spondylarthritis : Relevance for treatment].

J Sieper1, D Poddubnyy2,3.   

Abstract

Although the pathogenesis of spondylarthritis (SpA) has been the subject of intensive research in recent years, the consequences for treatment are relatively minor. Basic research studies indicated a potentially important role of the cytokines tumor necrosis factor (TNF) alpha and interleukin (IL)-17 for the pathogenesis of SpA but their outstanding role could then only be demonstrated by their inhibition in clinical studies, while other promising targets, such as IL‑23 and IL‑6 could not be shown to be relevant (at least against axial manifestations) in clinical studies. The intestinal microbiota probably plays an important role in the pathogenesis but not yet for the treatment of SpA. Ultimately, early effective and long-term suppression of inflammation is currently the best method to prevent ankylosis in the long run.

Entities:  

Keywords:  Ankylosis; Interleukin-17; Microbiota; Spondylitis; Tumor necrosis factor alpha

Mesh:

Substances:

Year:  2020        PMID: 31506791     DOI: 10.1007/s00393-019-00708-y

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  41 in total

Review 1.  Investigation of involved tissue in axial spondyloarthritis--what have we learnt from immunohistochemical studies?

Authors:  Denis Poddubnyy; Heiner Appel; Joachim Sieper
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-10       Impact factor: 4.098

2.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

Review 3.  Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis.

Authors:  Ellen M Gravallese; Georg Schett
Journal:  Nat Rev Rheumatol       Date:  2018-11       Impact factor: 20.543

4.  What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both?

Authors:  Denis Poddubnyy; Joachim Sieper
Journal:  Rheumatology (Oxford)       Date:  2018-07-01       Impact factor: 7.580

5.  Periodontal condition is associated with disease duration and motoric disabilities in patients with ankylosing spondylitis: results of a cross-sectional study.

Authors:  Dirk Ziebolz; David Douglas; Donya Douglas; Jan Schmickler; Daniel Patschan; Gerhard A Müller; Rainer Haak; Jana Schmidt; Gerhard Schmalz; Susann Patschan
Journal:  Rheumatol Int       Date:  2018-03-20       Impact factor: 2.631

Review 6.  A possible link between ankylosing spondylitis and periodontitis: a systematic review and meta-analysis.

Authors:  Tiara Ratz; Linda E Dean; Fabiola Atzeni; Christopher Reeks; Gary J Macfarlane; Tatiana V Macfarlane
Journal:  Rheumatology (Oxford)       Date:  2014-09-10       Impact factor: 7.580

7.  Human mast cells capture, store, and release bioactive, exogenous IL-17A.

Authors:  Troy Noordenbos; Iris Blijdorp; Sijia Chen; Jan Stap; Erik Mul; Juan D Cañete; Erik Lubberts; Nataliya Yeremenko; Dominique Baeten
Journal:  J Leukoc Biol       Date:  2016-03-31       Impact factor: 4.962

8.  Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS).

Authors:  Joachim Sieper; Joachim Listing; Denis Poddubnyy; In-Ho Song; Kay-Geert Hermann; Johanna Callhoff; Uta Syrbe; Jürgen Braun; Martin Rudwaleit
Journal:  Ann Rheum Dis       Date:  2015-08-04       Impact factor: 19.103

9.  Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort.

Authors:  Liesbet Van Praet; Lennart Jans; Philippe Carron; Peggy Jacques; Elien Glorieus; Roos Colman; Heleen Cypers; Herman Mielants; Martine De Vos; Claude Cuvelier; Filip Van den Bosch; Dirk Elewaut
Journal:  Ann Rheum Dis       Date:  2013-11-25       Impact factor: 19.103

10.  IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells.

Authors:  Jonathan P Sherlock; Barbara Joyce-Shaikh; Scott P Turner; Cheng-Chi Chao; Manjiri Sathe; Jeff Grein; Daniel M Gorman; Edward P Bowman; Terrill K McClanahan; Jennifer H Yearley; Gérard Eberl; Christopher D Buckley; Robert A Kastelein; Robert H Pierce; Drake M Laface; Daniel J Cua
Journal:  Nat Med       Date:  2012-07-01       Impact factor: 53.440

View more
  1 in total

Review 1.  [Spondyloarthritis in childhood and adulthood].

Authors:  Toni Hospach; Gerd Horneff; Denis Poddubnyy
Journal:  Z Rheumatol       Date:  2022-01-05       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.